ClinicalTrials.gg
RecruitingNCT06978088Updated Aug 14, 2025

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

A Phase 2 interventional study of LP-168 and Obinutuzumab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma and CLL/SLL, sponsored by Zulfa Omer. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by Zulfa Omer · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States — 136 open to participants now, 251 under way, 34 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · United States.

Planned enrollment
672nd of 1,298
34 · median 36
Started
2025
with 32 others
Phase 2
546 of 1,501
47 open now
Primary completion
2029-06
later than 197 of 247 live
Registered
1,455th of 1,501
by date

Among the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, this one is the 672nd largest by planned enrollment of the 1,298 interventional ones that give a count, is one of 33 that started in 2025, is one of 546 in phase 2, reaches primary completion later than 197 of the 247 other live ones, and was the 1,455th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

136 of the 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States are open now. Recruiting first, the newest first:

131 more — sign in →

All 136 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,501 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in United States, or all of them as a file.
02

Study summary

Multicenter Parallel 2 Cohort Phase 2 Study of LP-168 and Obinutuzumab for Previously Treated, and T474 Gatekeeper Mutant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This.

Read the detailed description

This is a multicenter parallel two cohort, phase II clinical trial designed to evaluate the combination of obinutuzumab + LP-168 for the treatment of: 1) previously treated, and 2) BTK T474I ( gate keeper mutation) mutated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) patients. The goal is to establish a safe dosing regimen for the combination and to acquire pilot data characterizing the effectiveness of the combination in increasing the depth of response as reflected in the rate of undetectable Minimal Residual Disease (MRD), complete response (CR). If successful, this would support a larger phase II/III study. A gatekeeper cohort of patients is added to further expand understanding of efficacy and translational biology of LP-168 in this patient population that represents a rapidly emerging unmet medical need in CLL.

Patients will receive LP-168 200 mg daily beginning day 1 of therapy for 12 cycles. Within 2 weeks of completing cycle 6, patients will undergo response evaluation that will include labs, CT scan, and bone marrow biopsy. Patients will then continue with LP-168 and then receive obinutuzumab for a total of 6 cycles, beginning cycle 7, days 1, 2, 8 and 15, and then day 1 of cycles 8-12. A minimum of 12 cycles of therapy will be administered. At end of Cycle 12 of therapy, patients will be assessed for treatment response and MRD status by labs, CT scans (if clinically indicated), peripheral blood and bone marrow morphology and using NGS Clonoseq (Adaptive Biotechnologies) for MRD status.

Patients with undetectable minimal residual disease (uMRD) CR at this time will have the option to discontinue therapy. Patients with less than CR or detectable MRD (dMRD) will continue therapy with LP-168 with follow up every 6 months. Patient and investigator may choose to repeat MRD testing from the bone marrow later during the disease course and stop therapy if uMRD is achieved. Patients with disease progression (PD) but who are gaining benefit from the drug can continue therapy per PI discretion.

03

Conditions studied

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Small Lymphocytic Lymphoma
  • CLL/SLL
  • Chronic Lymphocytic Leukemia

Keywords

  • LP-168
  • Obinutuzumab
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of CLL or SLL meeting criteria established in the 2018 iwCLL criteria and requiring treatment. Patients with variation in flow cytometry findings will be allowed to enroll if cytogenetics and/or mutational studies are supportive of CLL/SLL variant.

    a) Note: Variation in flow cytometry is defined as patients who have atypical immunophenotyping for CLL (CD5 negative, CD23 negative or surface expression of CD79b that is bright ) but clinically behave like CLL (leukocytosis, lymphadenopathy and splenomegaly) and have the FISH/Cytogenetics translocations(del 13q, trisomy 12, Del11q) or genomic features (XPO1, NOTCH1, SF3B1, FBXW7, MYD88, BIRC3, TRAF3, NFKBIE, SAMHD1, POT1, HIST1H1E, CHD2, ZMYM3, EGR2 and others) that are suggestive of CLL.

  2. Meet the criteria for inclusion into at least one of the following 2 cohorts:

    1. Cohort 1: One or more prior therapies for CLL/SLL including BCL2 inhibitor (BCL2i), and/or chemotherapy and/or BTK inhibitor (BTKi).

      • Note: Patients can be eligible if their CLL/SLL has been non-responsive to a covalent and noncovalent BTKi. Patients intolerant to BTKi whose disease becomes resistant to a second one are eligible to enroll. Prior treatment with CD20 will not be exclusionary.
    2. Cohort 2: Treatment with a prior BTKi (covalent and noncovalent) and have a BTK gatekeeper mutation in the T474 coordinate.
  3. Age ≥18 years.
  4. performance status ≤2 (or ≥60%, see Appendix A).
  5. Patients must have adequate organ and marrow function as defined below:

    1. ≥1,000/mcL, unless if neutropenia is due to underlying CLL bone marrow disease.
    2. ≥ 50,000/ µL unless if thrombocytopenia is due to underlying CLL bone marrow disease then platelets of ≥20,000 is acceptable
    3. Total ≤1.5 x (excepting Gilbert's syndrome, who may have a bilirubin > 1.5 × ULN, per discussion between the Investigator and the UC PI).
    4. and ALT ≤2.5 × ULN.
    5. Estimated (by Modification of Diet in Renal Disease [MDRD]) or Chronic Kidney Disease Epidemiology [CKD-EPI]) ≥ 30 mL/min
  6. Women of and non-sterile males must practice at least 1 of the following methods of with their partner(s) throughout the study and for 30 days after discontinuing study drug:

    1. Total abstinence from sexual intercourse as the preferred lifestyle of the patient; periodic abstinence is not acceptable.
    2. Surgically sterile partner(s) by vasectomy, bilateral orchiectomy, bilateral tubal ligation, bilateral oophorectomy, or hysterectomy.
    3. Intrauterine device.
    4. Hormonal contraceptives (oral, parenteral, vaginal ring or transdermal) for at least 1-month prior to study drug administration.
  7. Women of childbearing potential must have a negative pregnancy result as follows: At Screening on a serum sample obtained within 7 days prior to the first study drug administration. If a urine pregnancy test at any timepoint during the study is positive or indeterminate, a serum pregnancy test will be performed for confirmation.
  8. Non-sterile males must refrain from sperm donation, from initial study drug administration until 30 days after the last dose of study drug.
  9. Able to provide .

Exclusion criteria

Exclusion Criteria:

  1. Patients with active Richter's transformation.
  2. Patient has received any of the following therapies within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of study drug, or has not recovered to ≤ Grade 1 adverse effect(s)/toxicity(s) of the previous therapy (other than alopecia):

    1. Any anti-cancer therapy including chemotherapy, biologic or immunotherapy, radiotherapy, etc.
    2. Any therapy, including targeted small molecule agents.
    3. For patients who come off BCR antagonist treatment (BTK inhibitors, PI3K inhibitors, etc.), allow for 5 half-lives as these patients progress quickly after treatment discontinuation and then remain eligible ( may be given during the washout to allow for disease control, see d below for details).
    4. When a patient's intercurrent health condition would require short term steroid use this should be discussed with the Investigator in consultation with the Medical Monitor. Steroids are allowed for disease control in those R/R patients when use is limited to 2-3 days to allow for control of the underlying disease. Steroids may be given during the washout to allow for disease control.
  3. Patients with uncontrolled intercurrent illness or any other significant condition(s) that would make participation in this protocol unreasonably hazardous, in the opinion of the Investigator.
  4. Patients who require anti-coagulation with warfarin or equivalent Vitamin K antagonist.
  5. Major surgery within 14 days prior to the first dose of study drug.
  6. Patients who have received the following medications or therapies within 5 half-lives or 14 days, whichever is shorter, prior to the first dose of study drug:

    1. Steroid therapy (at dosages equivalent to prednisone >20 mg/day) for anti- neoplastic intent (except as noted in exclusion criterion #2).
    2. Cytochrome P450, family 3, subfamily A () strong inhibitors and strong CYP2C8 inducers/inhibitors (see the list in Appendix B)
    3. Strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort (Appendix B)
    4. There is a 28-day washout period required for patients who have had prior CAR T treatment if there is no evidence of cytokine release syndrome (CRS) or other AEs related to the CAR T treatment per discussion with the UC PI; reduced washout period may be acceptable after discussion with UC PI.
    5. Drugs that are substrates of MATE1 and MATE2-K should be avoided or substituted for other medications if possible. Use of these (if done) must be discussed with the PI of the study. (Appendix D).
  7. Patient has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or Star fruit within 3 days prior to the first dose of study drug.
  8. Patient requires treatment with systemic acid-reducing agents, H2 blocking agent and proton pump inhibitors, with the following exceptions:

    1. Proton pump inhibitors should be discontinued at least 7 days or at least 5-half-lives (whichever is shorter) prior and held throughout the study.
    2. If concurrent use of an H2 blocking agent is necessary, it must be administered only between 2 and 3 hours after the dose of LP-168. If not taken during this time, the dose of H2 blocking agents should not be taken again until 2 - 3 hours after the next dose of LP-168.
    3. If concurrent use of a local antacid is necessary, it must be administered 2 or more hours before and/or 2 or more hours after the dose of LP-168.
  9. Patient has clinically significant screening (ECG) abnormalities including:

    1. 2nd degree AV block type II, 3rd degree block, Grade 2 or higher bradycardia, and interval (QTcF) ≥ 480ms (calculated per Fridericia's formula [QTcF = QT/RR (1/3)]).
    2. For patients with presence of right bundle branch block (RBBB) or left bundle branch block (LBBB), cardiology review is needed to correct QTcF calculation using Sponsor recommended formula (Simplified Formula for Bundle Branch Block). See Appendix C.
    3. Other clinically significant ECG abnormalities per PI discretion.
  10. Patient has significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 180 days prior to the first dose of study drug, or any Class 3 or 4 cardiac disease as defined by the Functional Classification or ≤ 40%.
  11. Patient has a history of stroke or intracranial hemorrhage within 180 days prior to the first dose of study drug.
  12. Patients who have undergone /allogeneic hematopoietic stem cell transplantation (HSCT) therapy within 60 days of the first dose of LP-168, or patients on therapy post-HSCT at the time of Screening, or currently with clinically significant (GVHD) as per treating physician (patients in relapse after allogeneic transplantation must be off treatment with systemic immunosuppressive agents for at least 4 weeks). The use of topical steroids and/or up to 20 mg/day prednisone or equivalent systemic steroids for ongoing GVHD is permitted.
  13. Pregnant women, those planning to become pregnant during the study, and/or breastfeeding women are ineligible for participation.
  14. Patients with known malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
  15. Known to any of the components of LP-168 (see Investigators Brochure for a list of components).
  16. Patients with active bleeding disorder.

    a) NOTE: Von Willebrand's disease or hemophilia will not be excluded if patient is on treatment and well controlled.

  17. Patient exhibits evidence of other clinically significant uncontrolled condition(s) including, but not limited to:

    1. Uncontrolled active systemic infection (bacterial, fungal, viral);
    2. Known poorly controlled (defined as less than 200 ) (HIV) or active or C infection (active hepatitis B defined as HBsAg positive, or HBcAb positive with detectable HBV DNA load; active defined as HCV antibody positive with HCV RNA positive)
    3. Unexplained fever > 38.3°C within 7 days prior to the first dose of study drug administration (if the fever is considered attributed to the patient's or an explained infection, the Patient may be enrolled at the discretion of the Investigator).
  18. Patient has a history of other active malignancies within the past 1 year prior to study entry, with the exception of:

    1. Breast cancer or prostate cancer on endocrine therapy with stable disease.
    2. Continuation of maintenance therapy in patients with adequately treated malignancy.
    3. Cancer with expected survival of 2 years or more or that will not confound evaluation of LP-168 treatment.
    4. Adequately treated in situ carcinoma of the cervix uteri.
    5. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin.
    6. Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
    7. Patients with active CNS involvement can be enrolled per Investigator discretion; patients with significant clinical symptoms, including any that require treatment with high dose steroid, will be excluded.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Cohort 1: One or more prior therapies for CLL/SLL including BCL2 inhibitor (BCL2i), and/or chemotherapy and/or BTK inhibitor (BTKi). • Note: Patients can be eligible if their CLL/SLL has been non-responsive to a covalent and noncovalent BTKi. Patients intolerant to BTKi whose disease becomes resistant to a second one are eligible to enroll. Prior treatment with CD20 will not be exclusionary.

    Drug: LP-168 · Drug: Obinutuzumab

  • Experimental
    Cohort 2

    Cohort 2: Treatment with a prior BTKi (covalent and noncovalent) and have a BTK gatekeeper mutation in the T474 coordinate. prior treatment with BCL2 or chemotherapy will not exclude patients

    Drug: LP-168 · Drug: Obinutuzumab

Interventions

  • DrugRocbrutinibStudies of RocbrutinibRocbrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive LP-168 200 mg daily beginning day 1 of therapy for 12 cycles.

  • Patients will with LP-168 and then receive obinutuzumab for a total of 6 cycles, beginning cycle 7, days 1, 2, 8 and 15, and then day 1 of cycles 8-12. A minimum of 12 cycles of therapy will be administered.

06

What researchers measure

Primary outcomes

  1. Complete remission/ Complete remission with incomplete count (CR/CRi) defined by the IWCLL 2018 criteria

    To assess the complete response (CR), complete response with incomplete marrow recovery (CRi) rate of LP-168 + obinutuzumab in each cohort following 12 cycles of treatment.

    Time frame: 12 months

Secondary outcomes

  1. Overall response rate- defined by the IWCLL 2018 criteria

    To assess the overall response rate to LP-168 (CR, CRi, PR, PR-L and nPR) in each cohort of CLL/SLL following 6 cycles of treatment. Each patient will be assigned one of the following categories: 1) complete response, 2) partial response/Partial response with lymphocytosis or nodular partial response, 3) stable disease, 4) progressive disease, 5) early death from malignant disease, 6) early death from toxicity, 7) early death because of other cause, or 9) unknown (not assessable, insufficient data). Note: By arbitrary convention, category 9 usually designates the "unknown" status of any type of data in a clinical database.

    Time frame: 6 months

  2. Safety and tolerability - CTCAE

    To assess the safety and tolerability of LP-168 given with obinutuzumab. We will monitor further for SAEs (CTCAE grade \>=3) continuously on trial by cohort. The exception is the first 6 patients enrolled (irrespective of cohort) will be evaluated as well for safety of the combination with respect to DLTs as defined by this protocol. Patients will be monitored for regular safety outside the combination using the toxicity monitoring Table 8, given we already have data confirming the safety of the single agent LP-168.

    Time frame: 6 years

  3. Undetectable minimal residual disease (MRD) complete remission (CR) after completion of cycle 12 of therapy defined by negative leukemia cell to the 10-6 using Clonoseq.

    To assess the rate of undetectable measurable residual disease (uMRD), defined by negative leukemia cell to the 10-6 using NGS technique (Clonoseq).

    Time frame: 12 months

  4. Duration of response (DOR), progression free survival (PFS) and overall survival (OS) of patients receiving LP-168 together with obinutuzumab in each cohort of patients.

    DOR defined as the time from receiving first treatment to disease progression or death for patients who achieve complete or partial response, PFS defined as the interval between the first treatment day to the first sign of disease progression or death from any cause, and OS, defined as time from starting treatment until death, all measured at completion of LP-168 with obinutuzumab treatment.

    Time frame: 6 years

  5. PK of LP-168 via time to reach maximum plasma concentration

    To characterize the pharmacokinetics (PK) of LP-168 following administration in participants via time to reach maximum plasma concentration

    Time frame: At the end of cycle 12 or 336 days from the start of LP-168 (each cycle is 28 days)

  6. PK of LP-168 via area under the concentration-time curve (AUC)

    To characterize the pharmacokinetics (PK) of LP-168 following administration in participants via area under the concentration-time curve (AUC)

    Time frame: At the end of cycle 12 or 336 days from the start of LP-168 (each cycle is 28 days)

  7. Pharmacokinetics (PK) of LP-168 via half-life

    To characterize the pharmacokinetics (PK) of LP-168 following administration in participants via half-life

    Time frame: At the end of cycle 12 or 336 days from the start of LP-168 (each cycle is 28 days)

  8. Pharmacokinetics (PK) of LP-168 via clearance rate

    To characterize the pharmacokinetics (PK) of LP-168 following administration in participants via clearance rate

    Time frame: At the end of cycle 12 or 336 days from the start of LP-168 (each cycle is 28 days)

  9. Pharmacokinetics (PK) of LP-168 fvia volume of distribution based on plasma concentration measurements

    To characterize the pharmacokinetics (PK) of LP-168 following administration in participants via volume of distribution based on plasma concentration measurements

    Time frame: At the end of cycle 12 or 336 days from the start of LP-168 (each cycle is 28 days)

  10. BTK occupancy expressed as the percentage of total BTK that is occupied by the drug LP-168 at the end of pretreatment

    BTK occupancy will be measured in peripheral blood mononuclear cells (PBMCs) and will be expressed as the percentage of total BTK that is occupied by the drug LP-168 at the end of pretreatment (0 days from the start of LP-168).

    Time frame: 0 days from the start of LP-168

  11. BTK occupancy expressed as the percentage of total BTK that is occupied by the drug LP-168 at the end of cycle 6 .

    BTK occupancy will be measured in peripheral blood mononuclear cells (PBMCs) and will be expressed as the percentage of total BTK that is occupied by the drug LP-168 at the end of cycle 6 (168 days from the start of LP-168).

    Time frame: 168 days from the start of LP-168

  12. BTK occupancy expressed as the percentage of total BTK that is occupied by the drug LP-168 at the end of cycle 12

    BTK occupancy will be measured in peripheral blood mononuclear cells (PBMCs) and will be expressed as the percentage of total BTK that is occupied by the drug LP-168 at the end of cycle 12(336 days from the start of LP-168)

    Time frame: 336 days from the start of LP-168

Other outcomes

  1. Signaling measured by immunoblot analysis

    Signaling:will isolate CD19+ CLL cells and perform immunoblot analysis for phospho BTK (pBTK)/BTK, pPCLG2/PLCG2, pAKT/AKT and pERK/ERK. at Screening, Baseline pre-treatment, Cycle 1 Day 8, Cycle 6 Day 1, and Cycle 12 Day 1 of therapy in cohort 2.

    Time frame: Screening (28 days prior to the first dose of trial treatment), Baseline pre-treatment (before C1D1 dosing), Cycle 1 Day 8, Cycle 6 Day 1, and Cycle 12 Day 1 of therapy in cohort 2. Each cycle is 28 days.

  2. Chemokines production measurement at specific timepoints

    Broad range of chemokines ( CCL3, CCL4, TNF-alpha, and BAFF )production will be measured at Screening, Baseline pre-treatment, Cycle 1 Day 8, Cycle 6 Day 1, and Cycle 12 Day 1 of therapy in cohort 2.

    Time frame: Screening (28 days prior to the first dose of trial treatment), Baseline pre-treatment (before C1D1 dosing), Cycle 1 Day 8, Cycle 6 Day 1, and Cycle 12 Day 1 of therapy in cohort 2. Each cycle is 28 days.

  3. Extracellular vesicles (EVs) production measured by the number of vesicles produced in CLL cells

    The number of vesicles produced in CLL cells at Screening, Baseline pretreatment (before C1D1 dosing), Cycle 1 Day 8, Cycle 1 Day 28, and the end of Cycles 6 and 12 of therapy for cohort 2

    Time frame: Baseline pretreatment (before C1D1 dosing), Cycle 1 Day 8, Cycle 1 Day 28, and the end of Cycles 6 and 12 of therapy for cohort 2. Each cycle is 28 days.

  4. Immune cell function by profiling of specific surface markers on immune cells,

    Immune cell function studies at Screening, Baseline, end of Cycle 1, 6, and 12 by profiling of specific surface markers on immune cells,

    Time frame: Screening (28 days prior to the first dose of trial treatment), Baseline pre-treatment (before C1D1 dosing), end of Cycle 1, 6, and 12. Each cycle is 28 days.

  5. Immune cell function by profile of pro-regulatory B-cell IL-10 production,

    Immune cell function studies at Screening, Baseline, end of Cycle 1, 6, and 12 by profile of pro-regulatory B-cell IL-10 production,

    Time frame: Screening (28 days prior to the first dose of trial treatment), Baseline pre-treatment (before C1D1 dosing), end of Cycle 1, 6, and 12. Each cycle is 28 days.

  6. Immune cell function by measuring T-cell proliferative capacity of cytokine production

    Immune cell function studies at Screening, Baseline, end of Cycle 1, 6, and 12 by measuring T-cell proliferative capacity of cytokine production

    Time frame: Screening (28 days prior to the first dose of trial treatment), Baseline pre-treatment (before C1D1 dosing), end of Cycle 1, 6, and 12. Each cycle is 28 days.

  7. Immune cell function by measuring NK cell antibody dependent cellular cytotoxicity (ADCC) with obinutuzumab ex vivo against autologous CLL cells

    Immune cell function studies at Screening, Baseline, end of Cycle 1, 6, and 12 by measuring NK cell antibody dependent cellular cytotoxicity (ADCC) with obinutuzumab ex vivo against autologous CLL cells

    Time frame: Screening (28 days prior to the first dose of trial treatment), Baseline pre-treatment (before C1D1 dosing), end of Cycle 1, 6, and 12. Each cycle is 28 days.

  8. Surface proteomics

    Single cell sequencing with surface proteomics at Screening, end of cycle 6 and 12 in cohort 2. examine CD19 selected bone marrow samples at cycle 6, and cycle 12 to assess both presence of T474I mutation in conjunction with other BTK (C481S) and other CLL mutations at baseline. This analysis will allow ability to assess ability of LP-168 (6 cycle sample) or LP-168 + obinutuzumab to diminish the BTK T474I mutation and also interrogate ability of other sub-clones with other CLL mutations to expand in this arena. Here we will use the Mission Bio Tapiestri DNA protein platform with a CLL specific panel that includes the coding region of BTK, PLCG2, GRB2, CBL and other common mutations identified in CLL or associated with resistance.

    Time frame: 12 months

  9. Mechanism of resistance

    Diagnosis to relapse analysis of samples using exon sequencing, RNA sequencing, proteomic studies and other biologic studies to discern mechanism of resistance.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2029, 48 months after the start.

Of 207 non-industry phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's planned 48 months is below that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
May 18, 2025
StartActual
Jun 1, 2025
Primary completionEst.
Jun 1, 2029
CompletionEst.
Jun 1, 2034
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06978088
Lead sponsor
Zulfa Omer
Responsible party
Zulfa Omer (Principal Investigator, University of Cincinnati) — Sponsor-investigator
First posted
May 18, 2025
Start date
Jun 1, 2025
Primary completion
Jun 1, 2029 (estimated)
Completion
Jun 1, 2034 (estimated)
Last update
Aug 14, 2025

Study contacts

UCCC Clinical Trials Office
Contact
cancer@uchealth.com
513-584-7698
Zulf Omer, MD
Contact

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocbrutinib

Start the discussion